Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Awad

Showing results (751-760 of 839) with videos related to

Pageof 84
Sort By:
The New England Journal of Medicine|June 4, 2013
Acquired resistance to crizotinib from a mutation in CD74-ROS1Mark M Awad, Ryohei Katayama, Michele McTigue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2025
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung CancerFederica Pecci, Rohit Thummalapalli, Stephanie L Alden, et al.
Cancer Discovery|March 29, 2014
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancerLuc Friboulet, Nanxin Li, Ryohei Katayama, et al.
EMBO Reports|April 19, 2023
Clostridium perfringens virulence factors are nonredundant activators of the NLRP3 inflammasomeAnukriti Mathur, Callum Kay, Yansong Xue, et al.
Nature Medicine|January 15, 2020
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alterationAlexander Drilon, Jeffrey W Clark, Jared Weiss, et al.
JCO Precision Oncology|February 8, 2024
Influence of <i>TP53</i> Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in <i>STK11</i>-Mutant Non-Small-Cell Lung CancerAbdul Rafeh Naqash, Charalampos S Floudas, Etan Aber, et al.
JTO Clinical and Research Reports|April 20, 2026
Sotorasib in Advanced <i>KRAS</i> G12C-Mutated NSCLC: Results From the Global Expanded Access Program, Including Patients With Poor Performance Status and a History of CNS MetastasesSilvia Novello, Natalie Maimon Rabinovich, Jin-Yuan Shih, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 31, 2026
Impact of KRAS Mutations and Co-Alterations on Outcomes in Stage III Non-Squamous Non-Small Cell Lung Cancer Treated with Chemoradiation and ImmunotherapyNikhil P Mankuzhy, Valentina Santo, Jacob Y Shin, et al.
JCO Precision Oncology|December 14, 2019
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung CancerNatalie I Vokes, David Liu, Biagio Ricciuti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 10, 2017
Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 BlockadeEsra A Akbay, Shohei Koyama, Yan Liu, et al.
Pageof 84

Showing results (751-760 of 839) with videos related to

Sort By:
Pageof 84
The New England Journal of Medicine|June 4, 2013
Acquired resistance to crizotinib from a mutation in CD74-ROS1Mark M Awad, Ryohei Katayama, Michele McTigue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2025
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung CancerFederica Pecci, Rohit Thummalapalli, Stephanie L Alden, et al.
Cancer Discovery|March 29, 2014
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancerLuc Friboulet, Nanxin Li, Ryohei Katayama, et al.
EMBO Reports|April 19, 2023
Clostridium perfringens virulence factors are nonredundant activators of the NLRP3 inflammasomeAnukriti Mathur, Callum Kay, Yansong Xue, et al.
Nature Medicine|January 15, 2020
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alterationAlexander Drilon, Jeffrey W Clark, Jared Weiss, et al.
JCO Precision Oncology|February 8, 2024
Influence of <i>TP53</i> Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in <i>STK11</i>-Mutant Non-Small-Cell Lung CancerAbdul Rafeh Naqash, Charalampos S Floudas, Etan Aber, et al.
JTO Clinical and Research Reports|April 20, 2026
Sotorasib in Advanced <i>KRAS</i> G12C-Mutated NSCLC: Results From the Global Expanded Access Program, Including Patients With Poor Performance Status and a History of CNS MetastasesSilvia Novello, Natalie Maimon Rabinovich, Jin-Yuan Shih, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 31, 2026
Impact of KRAS Mutations and Co-Alterations on Outcomes in Stage III Non-Squamous Non-Small Cell Lung Cancer Treated with Chemoradiation and ImmunotherapyNikhil P Mankuzhy, Valentina Santo, Jacob Y Shin, et al.
JCO Precision Oncology|December 14, 2019
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung CancerNatalie I Vokes, David Liu, Biagio Ricciuti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 10, 2017
Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 BlockadeEsra A Akbay, Shohei Koyama, Yan Liu, et al.
Pageof 84